Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

LGND

Ligand Pharmaceuticals (LGND)

Ligand Pharmaceuticals Incorporated
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LGND
DateTimeSourceHeadlineSymbolCompany
08/03/202405:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
07/03/202409:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
06/03/202410:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
02/03/202408:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/03/202410:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/03/202410:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/03/202410:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/03/202410:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/03/202408:49Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
29/02/202410:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
29/02/202409:43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
27/02/202423:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LGNDLigand Pharmaceuticals Incorporated
17/02/202412:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
17/02/202412:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
17/02/202412:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
17/02/202412:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
14/02/202422:26Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
14/02/202407:39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
13/02/202411:42Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
11/01/202411:30GlobeNewswire Inc.Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy LasofoxifeneNASDAQ:LGNDLigand Pharmaceuticals Incorporated
06/01/202409:40Dow Jones NewsLigand Pharmaceuticals Gets FDA OK for Viral Skin Infection TreatmentNASDAQ:LGNDLigand Pharmaceuticals Incorporated
05/01/202408:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
05/01/202408:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
07/12/202307:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
07/12/202307:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
02/12/202300:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LGNDLigand Pharmaceuticals Incorporated
02/12/202300:20GlobeNewswire Inc.Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical IndicationsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
29/11/202301:01GlobeNewswire Inc.Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer SymposiumNASDAQ:LGNDLigand Pharmaceuticals Incorporated
10/11/202313:48Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
10/11/202309:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
 Showing the most relevant articles for your search:NASDAQ:LGND